NCT03526354View on ClinicalTrials.gov

Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
SchizophreniaSchizoaffective DisorderSubstance Use Disorders
Interventions
DRUG

Brexpiprazole

Brexpiprazole 4mg daily for 12 weeks

OTHER

Treatment as Usual

Current antipsychotic medication for 12 weeks

Trial Locations (4)

27599

University of North Carolina, Chapel Hill

30912

Augusta University, Augusta

02114

Massachusetts General Hospital, Boston

01655

UMass Medical School, Worcester

Sponsors
All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

University of North Carolina, Chapel Hill

OTHER

collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

Augusta University

OTHER

lead

University of Massachusetts, Worcester

OTHER